NL-OMON23641招募中不适用

Early detection of cardiac dysfunction in childhood cancer survivors; a DCOG LATER study

Princess Maxima Center for pediatric oncology, Amsterdam UMC (AMC), Radboudumc, SKIO0 个研究点目标入组 2,200 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

暂无简介。

•Eligible survivors are 5-year childhood cancer survivors (CCS) diagnosed before the age of 18 years, between 1/1/1963 and 12/31/2001 with a malignancy according to the third edition of the International Classification of Childhood Cancer. We only included CCS who were living in the Netherlands at the time of childhood cancer diagnosis and who were treated in one of the Dutch pediatric oncology/hematology centers (Academic Medical Center Amsterdam, VU University Medical Center, Leiden University Medical Center, Erasmus Medical Center, University Medical Center Groningen, Radboudumc, and University Medical Center Utrecht). This study will include 4 risk groups; risk group 1: CCS who have received anthracyclines, mitoxantrone, or irradiation to the heart region; risk group 2 (max n=100): cyclophosphamide only (no anthracyclines, mitoxantrone, or irradiation to the heart region, ifosfamide or vincristine); risk group 3 (max n=100): ifosfamide only (no anthracyclines, mitoxantrone, or irradiation to the heart region, cyclophosphamide or vincristine); risk group 4 (max n=100): vincristine only (no anthracyclines, mitoxantrone, or irradiation to the heart region, ifosfamide or cyclophosphamide), irrespective current age. For the comparison group 500 healthy siblings will be included.

发起方

Princess Maxima Center for pediatric oncology, Amsterdam UMC (AMC), Radboudumc, SKIO